Visualitzant O - Articles científics per títol

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

Figlioli, Gisella; Kvist, Anders; Tham, Emma; Soukupova, Jana; Kleiblova, Petra; Muranen, Taru A; Balmaña Gelpí, Judith; Diez Gibert, Orland (MDPI, 2020-01-26)

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

Morancho Armisen, Beatriz; Román Alonso, Macarena; Ovejero Romero, Pablo; Arribas López, Joaquin Vicente; Arenas Lahuerta, Enrique Javier; Martínez-Sabadell, Alex; Rius Ruiz, Irene; Escorihuela Baez, Marta (Cell Press, 2022-10-18)

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

De Mattos-Arruda, Leticia; Cortés Castan, Javier; Blanco-Heredia, Juan; Tiezzi, Daniel G.; Gonçalves Ribeiro, Samuel; Ortega Cebrian, Vanesa; Cusco Pons, Pol; Fasani, Roberta; Nuciforo, Paolo Giovanni; Rubio Rodríguez, Isabel Teresa; Villacampa Javierre, Guillermo; Dienstmann, Rodrigo (Nature Research, 2021-06-07)

The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

Berastegui Zufiaurre, Nerea; Ainciburu, Marina; Romero, Juan P.; García-Olloqui, Paula; Philippe, Céline; Molero Yordi, Antonieta; Montoro Gómez, Maria Julia; Tazón Vega, Bárbara; Valcarcel Ferreiras, David; Alfonso-Piérola, Ana (Nature Portfolio, 2022-12-09)

The trophectoderm acts as a niche for the inner cell mass through C/EBPα-regulated IL-6 signaling

Plana-Carmona, Marcos; Stik, Grégoire; Bulteau, Romain; Segura Morales, Carolina; Alcazar Perez, Noelia; Wyatt, Chris; Tian, Tian V; Vila Casadesus, Maria (Cell Press, 2022-09-13)

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)

Miguel-Huguet, Bernat; Perez-Garcia, Jose Manuel; Llombart-Cussac, Antonio; Cortés Castan, Javier; Pérez López, Jorge; Sampayo-Cordero, Miguel; Malfettone, Andrea (MDPI, 2020-09-10)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Duro Sánchez, Santiago; Nadal Serrano, Mercedes; Lalinde-Gutiérrez, Marta; Morancho Armisen, Beatriz; Pérez-Ramos, Sandra; Escriva de Romaní Muñoz, Santiago Ignacio; Gandullo Sánchez, Lucía; Rodilla Benito, Verónica; Cortés Castan, Javier; Arribas López, Joaquin Vicente; Bernadó Morales, Cristina; Arenas Lahuerta, Enrique Javier; Saura Manich, Cristina; Escorihuela Baez, Marta (American Association for Cancer Research, 2022-12-16)

Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies

Pérez del Río, Eduardo; Roman Alonso, Macarena; Rius Ruiz, Irene; Santos, Fabião; Castellote Borrell, Miquel; Veciana, Jaume; Arribas, Joaquin (Elsevier, 2023-12)

Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study

Augustinus, Simone; van Laarhoven, H.W.M.; Cirkel, Geert A.; de Groot, Jan Willem B.; Groot Koerkamp, Bas; Macarulla, Teresa (MDPI, 2023-11-27)

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

Ajani, Jaffer A; FARID, EL HAJBI; Cunningham, David; Thuss-Patience, Peter; Scagliotti, Giorgio; Alsina, Maria (Elsevier, 2024-01)

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

Moore, Kathleen N; Oaknin Benzaquen, Ana Mazaltob; Friedlander, Michael; Lisyanskaya, Alla; Scambia, Giovanni; Colombo, Nicoletta (Elsevier, 2021-10)

Towards a cancer mission in Horizon Europe: recommendations

Ringborg, Ulrik; Celis, Julio E.; Aaronson, Neil; Abou-Zeid, Nancy; Tabernero Caturla, Josep; Berns, Anton; Heitor, Manuel (Wiley, 2020-08)

Towards evidence-based response criteria for cancer immunotherapy

Laurie, Scott; Seymour, Lesley; de Vries, Elisabeth; GARRALDA, Elena (Nature Portfolio, 2023-05-24)

Transcriptional response to metal starvation in the emerging pathogen Mycoplasma genitalium is mediated by Fur-dependent and –independent regulatory pathways

Martínez-Torró, Carlos; Torres-Puig, Sergi; Monge Azemar, Marta; Sánchez-Alba, Lucía; González-Martín, Miguel; Marcos-Silva, Marina; Canals Suris, Francesc (Taylor and Francis, 2020-12-20)

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

Feng, Helian; Gusev, Alexander; Pasaniuc, Bogdan; Wu, Lang; Long, Jirong; Abu‐full, Zomoroda; Balmaña Gelpí, Judith; Diez Gibert, Orland (Wiley, 2020-07)

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

Lazar, Vladimir; Girard, Nicolas; Raymond, Eric; Martini, Jean-François; Galbraith, Susan; Raynaud, Jacques; Felip Font, Enriqueta; Tabernero Caturla, Josep (American Society of Clinical Oncology, 2022-09-15)

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

León-Román, Juan; Bolufer Cardona, Monica; Sánchez-Salinas, Mario; Alonso-Martínez, Carla; Bestard, Oriol; IACOBONI, GLORIA; Bermejo García, Sheila; Cecilia del Carmen, Carpio Segura; Garcia-Carro, Clara; Barba, Pere; Soler, María José (Oxford University Press, 2024-03)

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Jerusalem, Guy; Park, Yeon Hee; Yamashita, Toshinari; Hurvitz, Sara; Modi, Shanu; André, Fabrice; Saura Manich, Cristina (American Association for Cancer Research, 2022-12-01)

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Modi, Shanu; Krop, Ian; Park, Yeon Hee; Kim, Sung‑Bae; Tamura, K.; Saura Manich, Cristina (Elsevier, 2024-03)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

López-Miranda, Elena; Perez-Garcia, Jose Manuel; Brain, Etienne; Ravnik, Maja; Escriva de Romaní Muñoz, Santiago Ignacio; Cortés Castan, Javier; Di Cosimo, Serena (MDPI, 2020-11-25)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

The trophectoderm acts as a niche for the inner cell mass through C/EBPα-regulated IL-6 signaling

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies

Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

Towards a cancer mission in Horizon Europe: recommendations

Towards evidence-based response criteria for cancer immunotherapy

Transcriptional response to metal starvation in the emerging pathogen Mycoplasma genitalium is mediated by Fur-dependent and –independent regulatory pathways

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases ﻿

The target antigen determines the mechanism of acquired resistance to T cell-based therapies ﻿

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers ﻿

The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes ﻿

The trophectoderm acts as a niche for the inner cell mass through C/EBPα-regulated IL-6 signaling ﻿

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II) ﻿

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer ﻿

Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies ﻿

Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study ﻿

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study ﻿

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial ﻿

Towards a cancer mission in Horizon Europe: recommendations ﻿

Towards evidence-based response criteria for cancer immunotherapy ﻿

Transcriptional response to metal starvation in the emerging pathogen Mycoplasma genitalium is mediated by Fur-dependent and –independent regulatory pathways ﻿

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status ﻿

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies ﻿

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies ﻿

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis ﻿

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01) ﻿

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

The trophectoderm acts as a niche for the inner cell mass through C/EBPα-regulated IL-6 signaling

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies

Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

Towards a cancer mission in Horizon Europe: recommendations

Towards evidence-based response criteria for cancer immunotherapy

Transcriptional response to metal starvation in the emerging pathogen Mycoplasma genitalium is mediated by Fur-dependent and –independent regulatory pathways

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial